<DOC>
	<DOCNO>NCT01226394</DOCNO>
	<brief_summary>Multicentric randomise trial . Patients high risk develop colorectal Peritoneal Carcinomatosis ( PC ) resection primary inform , sign consent pre-registered . All patient receive current standard adjuvant treatment : 6 month systemic chemotherapy ( currently Folfox-4 regimen could modify standard modify ) . Then work-up do exclude recurrence . The likelihood recurrence low occurs , patient randomise treated best know treatment . If work-up negative , patient randomise surveillance alone ( control group ) exploratory laparotomy + HIPEC ( experimental group ) .</brief_summary>
	<brief_title>Trial Comparing Simple Follow-up Exploratory Laparotomy Plus `` Principle '' ( Hyperthermic Intraperitoneal Chemotherapy ) HIPEC Colorectal Patients</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Rupture</mesh_term>
	<mesh_term>Fever</mesh_term>
	<mesh_term>Krukenberg Tumor</mesh_term>
	<criteria>A ) Patients present follow history : 1 . Histologicallyproven colorectal adenocarcinoma 2 . Presenting time resection primary one follow 4 criterion ( criterion indicate high risk develop PC ) : Minimal PC , resect time primary Ovarian metastasis Rupture primary tumour inside peritoneal cavity , Iatrogenic rupture primary tumour surgery B ) Who receive standard systemic adjuvant chemotherapy ( 6 month systemic chemotherapy ) : Chemotherapy Folfox 4 regimen ( current standard treatment ; modify future two group , standard modified… ) . Given intenttotreat basis ( stop prematurely miscellaneous reasons… ) ; C ) Patients present sign tumour recurrence end 6 month chemotherapy . D ) Patients follow general characteristic : 1 . Age 18 70 year , 2 . Performance Status WHO &lt; 2 , life expectancy &gt; 12 week , 3 . Haematological parameter : Polynuclear neutrophils ³ 1.5x109/L , platelet ³ 100x109/L , 4 . Liver function : Total Bilirubin £ 1.5 x ULN , AST ( SGOT ) et ALT ( SGPT ) £ 3 x ULN , alkaline phosphatase £ 3 x ULN , 5 . Renal function : Plasma creatinine £ 1,25 x ULN , 6 . Operable patient , 7 . Grade £ 2 peripheral neuropathy ( CTC AE v3.0 annex 7 ) 8 . Patients entitle French National Health Insurance coverage . E ) Patients informed sign consent form obtain initiating procedure specific trial . 1 . Cancers non colorectal origin , particularly , appendiceal cancer exclude 2 . Patients present detectable recurrent tumour 3 . Grade ≥ 3 Peripheral neuropathy 4 . History cancer ( except cutaneous basocellullar cancer situ carcinoma uterine cervix ) recurrence 5 previous year 5 . Patients already include another trial concern firstline treatment 6 ) Pregnant woman likely pregnant 7 ) Persons guardianship 8 ) Followup impossible geographic , social psychological reason</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>peritoneal carcinomatosis</keyword>
	<keyword>HIPEC</keyword>
	<keyword>control clinical trial</keyword>
</DOC>